

Table I-17

Lifetime Risk (Percent) of Dying from Cancer by Site and Race/Ethnicity

Both Sexes, Total U.S., 2002-2004

Site	All Races		Whites		Blacks	
	Percent	(95% C.I.)	Percent	(95% C.I.)	Percent	(95% C.I.)
All Sites	21.29	(21.26, 21.32)	21.45	(21.42, 21.49)	21.31	(21.22, 21.40)
Oral Cavity and Pharynx	0.28	(0.28, 0.29)	0.28	(0.27, 0.28)	0.33	(0.32, 0.34)
Esophagus	0.48	(0.47, 0.48)	0.48	(0.47, 0.49)	0.51	(0.49, 0.52)
Stomach	0.46	(0.46, 0.47)	0.41	(0.41, 0.42)	0.74	(0.72, 0.76)
Colon and Rectum	2.20	(2.19, 2.21)	2.18	(2.17, 2.19)	2.42	(2.39, 2.46)
Liver and Intrahepatic Bile Duct	0.54	(0.53, 0.54)	0.50	(0.50, 0.51)	0.58	(0.57, 0.60)
Pancreas	1.20	(1.19, 1.21)	1.20	(1.19, 1.20)	1.26	(1.24, 1.29)
Larynx	0.14	(0.13, 0.14)	0.13	(0.13, 0.13)	0.21	(0.20, 0.22)
Lung and Bronchus	5.99	(5.97, 6.00)	6.13	(6.11, 6.15)	5.50	(5.45, 5.55)
Melanoma of the Skin	0.28	(0.27, 0.28)	0.31	(0.31, 0.32)	0.04	(0.03, 0.04)
Breast	1.53	(1.52, 1.54)	1.52	(1.51, 1.53)	1.73	(1.70, 1.76)
Urinary Bladder	0.53	(0.52, 0.53)	0.56	(0.55, 0.56)	0.36	(0.35, 0.38)
Kidney and Renal Pelvis	0.46	(0.46, 0.47)	0.48	(0.47, 0.49)	0.36	(0.35, 0.38)
Brain and Other Nervous System	0.43	(0.43, 0.44)	0.47	(0.46, 0.47)	0.22	(0.21, 0.23)
Thyroid	0.05	(0.05, 0.05)	0.05	(0.05, 0.06)	0.04	(0.04, 0.04)
Hodgkin Lymphoma	0.04	(0.04, 0.05)	0.05	(0.04, 0.05)	0.03	(0.03, 0.03)
Non-Hodgkin Lymphoma	0.83	(0.83, 0.84)	0.88	(0.88, 0.89)	0.45	(0.44, 0.47)
Myeloma	0.42	(0.42, 0.43)	0.40	(0.40, 0.41)	0.64	(0.62, 0.66)
Leukemia	0.83	(0.83, 0.84)	0.87	(0.86, 0.88)	0.60	(0.58, 0.62)
Acute Lymphocytic Leukemia	0.04	(0.04, 0.04)	0.04	(0.04, 0.05)	0.03	(0.02, 0.03)
Chronic Lymphocytic Leukemia	0.19	(0.18, 0.19)	0.20	(0.19, 0.20)	0.14	(0.13, 0.15)
Acute Myeloid Leukemia	0.30	(0.30, 0.30)	0.31	(0.31, 0.32)	0.19	(0.18, 0.20)
Chronic Myeloid Leukemia	0.05	(0.05, 0.05)	0.05	(0.05, 0.05)	0.04	(0.04, 0.05)

Devcan Version 6.2.0, April 2007, National Cancer Institute (<http://srab.cancer.gov/devcan/>).

Source: NCHS public use data file for the total US.

Table I-17 - continued

Lifetime Risk (Percent) of Dying from Cancer by Site and Race/Ethnicity

Both Sexes, Total U.S., 2002-2004

Site	Asian/Pacific Islanders	American Indian/ Alaska Natives ^a	Hispanics ^b
	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)
All Sites	18.32 (18.04, 18.61)	16.87 (16.34, 17.43)	17.39 (17.23, 17.55)
Oral Cavity and Pharynx	0.32 (0.28, 0.37)	0.24 (0.18, 0.34)	0.22 (0.20, 0.24)
Esophagus	0.30 (0.26, 0.35)	0.40 (0.32, 0.52)	0.31 (0.29, 0.33)
Stomach	1.32 (1.24, 1.42)	0.73 (0.62, 0.89)	0.91 (0.87, 0.95)
Colon and Rectum	2.17 (2.05, 2.29)	1.86 (1.66, 2.09)	1.92 (1.86, 1.98)
Liver and Intrahepatic Bile Duct	1.54 (1.46, 1.63)	0.88 (0.75, 1.05)	0.99 (0.95, 1.03)
Pancreas	1.21 (1.14, 1.29)	0.80 (0.68, 0.96)	1.13 (1.09, 1.18)
Larynx	0.07 (0.05, 0.10)	0.09 (0.06, 0.17)	0.12 (0.11, 0.14)
Lung and Bronchus	4.12 (3.99, 4.25)	4.13 (3.88, 4.42)	3.17 (3.10, 3.24)
Melanoma of the Skin	0.06 (0.04, 0.09)	0.13 (0.08, 0.24)	0.10 (0.08, 0.11)
Breast	0.94 (0.87, 1.00)	1.01 (0.88, 1.19)	1.11 (1.07, 1.16)
Urinary Bladder	0.36 (0.31, 0.42)	0.23 (0.15, 0.35)	0.39 (0.36, 0.42)
Kidney and Renal Pelvis	0.26 (0.22, 0.30)	0.68 (0.58, 0.82)	0.48 (0.45, 0.51)
Brain and Other Nervous System	0.25 (0.22, 0.29)	0.18 (0.14, 0.27)	0.32 (0.30, 0.34)
Thyroid	0.09 (0.07, 0.12)	0.06 (0.03, 0.14)	0.07 (0.06, 0.08)
Hodgkin Lymphoma	0.04 (0.03, 0.06)	0.04 (0.02, 0.12)	0.05 (0.04, 0.06)
Non-Hodgkin Lymphoma	0.79 (0.72, 0.86)	0.52 (0.41, 0.66)	0.74 (0.71, 0.78)
Myeloma	0.25 (0.22, 0.29)	0.41 (0.32, 0.53)	0.40 (0.38, 0.43)
Leukemia	0.56 (0.51, 0.62)	0.49 (0.40, 0.62)	0.63 (0.60, 0.66)
Acute Lymphocytic Leukemia	0.04 (0.03, 0.06)	0.05 (0.03, 0.13)	0.06 (0.06, 0.07)
Chronic Lymphocytic Leukemia	0.05 (0.03, 0.08)	0.07 (0.04, 0.16)	0.09 (0.07, 0.10)
Acute Myeloid Leukemia	0.24 (0.21, 0.28)	0.18 (0.13, 0.27)	0.21 (0.20, 0.23)
Chronic Myeloid Leukemia	0.04 (0.02, 0.06)	0.04 (0.02, 0.11)	0.04 (0.04, 0.05)

Devcan Version 6.2.0, April 2007, National Cancer Institute (<http://srab.cancer.gov/devcan/>).

Source: NCHS public use data file for the total US.

^a Underlying mortality data for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.^b Hispanic is not mutually exclusive from whites, blacks, Asian Pacific Islanders, and American Indians/Alaska Natives. Underlying mortality data for Hispanics exclude deaths from Minnesota, New Hampshire and North Dakota.

Table I-18

Lifetime Risk (Percent) of Dying from Cancer by Site and Race/Ethnicity

Males, Total U.S., 2002-2004

Site	All Races		Whites		Blacks	
	Percent	(95% C.I.)	Percent	(95% C.I.)	Percent	(95% C.I.)
All Sites	23.31	(23.27, 23.36)	23.41	(23.36, 23.46)	23.70	(23.56, 23.84)
Oral Cavity and Pharynx	0.39	(0.38, 0.39)	0.37	(0.36, 0.38)	0.51	(0.49, 0.53)
Esophagus	0.75	(0.74, 0.76)	0.77	(0.76, 0.78)	0.74	(0.72, 0.77)
Stomach	0.56	(0.56, 0.57)	0.51	(0.50, 0.52)	0.87	(0.84, 0.90)
Colon and Rectum	2.29	(2.27, 2.30)	2.28	(2.26, 2.29)	2.41	(2.36, 2.47)
Liver and Intrahepatic Bile Duct	0.69	(0.69, 0.70)	0.65	(0.64, 0.66)	0.78	(0.75, 0.80)
Pancreas	1.20	(1.19, 1.21)	1.21	(1.20, 1.22)	1.18	(1.15, 1.21)
Larynx	0.23	(0.22, 0.23)	0.21	(0.21, 0.22)	0.37	(0.35, 0.39)
Lung and Bronchus	7.12	(7.09, 7.14)	7.20	(7.17, 7.23)	7.09	(7.01, 7.17)
Melanoma of the Skin	0.37	(0.36, 0.37)	0.42	(0.41, 0.42)	0.04	(0.03, 0.04)
Breast	0.03	(0.03, 0.03)	0.03	(0.03, 0.03)	0.04	(0.03, 0.05)
Prostate	2.87	(2.85, 2.89)	2.70	(2.68, 2.72)	4.50	(4.43, 4.58)
Testis	0.02	(0.02, 0.02)	0.02	(0.02, 0.02)	0.01	(0.01, 0.02)
Urinary Bladder	0.78	(0.77, 0.79)	0.83	(0.82, 0.84)	0.40	(0.38, 0.42)
Kidney and Renal Pelvis	0.59	(0.58, 0.60)	0.62	(0.61, 0.63)	0.45	(0.43, 0.47)
Brain and Other Nervous System	0.48	(0.47, 0.49)	0.52	(0.51, 0.53)	0.23	(0.22, 0.25)
Thyroid	0.04	(0.04, 0.05)	0.05	(0.04, 0.05)	0.03	(0.02, 0.03)
Hodgkin Lymphoma	0.05	(0.05, 0.05)	0.05	(0.05, 0.05)	0.04	(0.03, 0.04)
Non-Hodgkin Lymphoma	0.91	(0.90, 0.92)	0.97	(0.96, 0.98)	0.47	(0.45, 0.49)
Myeloma	0.46	(0.45, 0.47)	0.44	(0.44, 0.45)	0.63	(0.60, 0.65)
Leukemia	0.98	(0.97, 0.99)	1.03	(1.01, 1.04)	0.65	(0.62, 0.68)
Acute Lymphocytic Leukemia	0.05	(0.05, 0.05)	0.05	(0.05, 0.05)	0.03	(0.03, 0.04)
Chronic Lymphocytic Leukemia	0.23	(0.22, 0.24)	0.24	(0.24, 0.25)	0.16	(0.15, 0.18)
Acute Myeloid Leukemia	0.35	(0.34, 0.35)	0.37	(0.36, 0.37)	0.20	(0.19, 0.22)
Chronic Myeloid Leukemia	0.05	(0.05, 0.06)	0.05	(0.05, 0.06)	0.05	(0.04, 0.06)

Devcan Version 6.2.0, April 2007, National Cancer Institute (<http://srab.cancer.gov/devcan/>).

Source: NCHS public use data file for the total US.

Table I-18 - continued

Lifetime Risk (Percent) of Dying from Cancer by Site and Race/Ethnicity

Males, Total U.S., 2002-2004

Site	Asian/Pacific Islanders	American Indian/ Alaska Natives ^a	Hispanics ^b
	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)
All Sites	20.73 (20.32, 21.16)	17.20 (16.42, 18.05)	19.80 (19.55, 20.06)
Oral Cavity and Pharynx	0.43 (0.37, 0.51)	0.32 (0.22, 0.53)	0.32 (0.29, 0.36)
Esophagus	0.47 (0.40, 0.55)	0.62 (0.48, 0.86)	0.48 (0.44, 0.52)
Stomach	1.54 (1.42, 1.69)	0.85 (0.68, 1.10)	1.07 (1.01, 1.14)
Colon and Rectum	2.30 (2.14, 2.48)	1.94 (1.66, 2.31)	2.10 (2.01, 2.20)
Liver and Intrahepatic Bile Duct	1.97 (1.86, 2.10)	0.86 (0.71, 1.12)	1.24 (1.18, 1.31)
Pancreas	1.14 (1.05, 1.25)	0.79 (0.60, 1.07)	1.06 (1.00, 1.12)
Larynx	0.13 (0.09, 0.19)	0.14 (0.08, 0.33)	0.24 (0.21, 0.27)
Lung and Bronchus	5.34 (5.14, 5.55)	4.58 (4.18, 5.06)	4.29 (4.17, 4.41)
Melanoma of the Skin	0.06 (0.04, 0.11)	0.10 (0.05, 0.28)	0.10 (0.08, 0.13)
Breast	0.01 (0.00, 0.05)	0.01 (0.00, 0.20)	0.02 (0.01, 0.04)
Prostate	2.29 (2.10, 2.50)	2.18 (1.82, 2.62)	3.19 (3.05, 3.33)
Testis	0.01 (0.00, 0.05)	0.01 (0.00, 0.19)	0.02 (0.02, 0.04)
Urinary Bladder	0.53 (0.45, 0.64)	0.30 (0.17, 0.54)	0.56 (0.51, 0.62)
Kidney and Renal Pelvis	0.34 (0.28, 0.43)	0.84 (0.69, 1.08)	0.63 (0.59, 0.69)
Brain and Other Nervous System	0.31 (0.26, 0.37)	0.22 (0.16, 0.41)	0.34 (0.31, 0.38)
Thyroid	0.06 (0.04, 0.11)	0.02 (0.00, 0.20)	0.06 (0.05, 0.08)
Hodgkin Lymphoma	0.04 (0.02, 0.08)	0.02 (0.00, 0.20)	0.05 (0.04, 0.07)
Non-Hodgkin Lymphoma	0.86 (0.77, 0.97)	0.44 (0.34, 0.65)	0.76 (0.71, 0.82)
Myeloma	0.26 (0.22, 0.32)	0.45 (0.30, 0.70)	0.42 (0.39, 0.46)
Leukemia	0.66 (0.59, 0.75)	0.49 (0.37, 0.72)	0.70 (0.66, 0.76)
Acute Lymphocytic Leukemia	0.04 (0.03, 0.08)	0.06 (0.03, 0.23)	0.06 (0.06, 0.08)
Chronic Lymphocytic Leukemia	0.08 (0.05, 0.14)	0.07 (0.03, 0.26)	0.11 (0.08, 0.14)
Acute Myeloid Leukemia	0.28 (0.24, 0.33)	0.17 (0.10, 0.36)	0.26 (0.23, 0.29)
Chronic Myeloid Leukemia	0.03 (0.02, 0.07)	0.04 (0.01, 0.22)	0.04 (0.03, 0.06)

Devcan Version 6.2.0, April 2007, National Cancer Institute (<http://srab.cancer.gov/devcan/>).

Source: NCHS public use data file for the total US.

^a Underlying mortality data for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.^b Hispanic is not mutually exclusive from whites, blacks, Asian Pacific Islanders, and American Indians/Alaska Natives. Underlying mortality data for Hispanics exclude deaths from Minnesota, New Hampshire and North Dakota.

Table I-19

Lifetime Risk (Percent) of Dying from Cancer by Site and Race/Ethnicity

Females, Total U.S., 2002-2004

Site	All Races		Whites		Blacks	
	Percent	(95% C.I.)	Percent	(95% C.I.)	Percent	(95% C.I.)
All Sites	19.74	(19.70, 19.78)	19.96	(19.91, 20.00)	19.39	(19.27, 19.51)
Oral Cavity and Pharynx	0.19	(0.18, 0.19)	0.19	(0.18, 0.19)	0.16	(0.15, 0.18)
Esophagus	0.22	(0.22, 0.23)	0.21	(0.21, 0.22)	0.30	(0.28, 0.31)
Stomach	0.38	(0.37, 0.38)	0.33	(0.33, 0.34)	0.62	(0.60, 0.65)
Colon and Rectum	2.13	(2.12, 2.14)	2.10	(2.09, 2.12)	2.44	(2.39, 2.49)
Liver and Intrahepatic Bile Duct	0.39	(0.39, 0.40)	0.37	(0.36, 0.38)	0.41	(0.39, 0.43)
Pancreas	1.19	(1.18, 1.20)	1.18	(1.17, 1.19)	1.33	(1.30, 1.37)
Larynx	0.06	(0.05, 0.06)	0.05	(0.05, 0.06)	0.07	(0.07, 0.08)
Lung and Bronchus	5.00	(4.98, 5.02)	5.20	(5.17, 5.22)	4.12	(4.06, 4.18)
Melanoma of the Skin	0.20	(0.19, 0.20)	0.22	(0.22, 0.23)	0.04	(0.03, 0.05)
Breast	2.89	(2.88, 2.91)	2.89	(2.87, 2.90)	3.23	(3.18, 3.28)
Cervix Uteri	0.24	(0.24, 0.24)	0.21	(0.21, 0.22)	0.43	(0.41, 0.45)
Corpus and Uterus, NOS	0.51	(0.51, 0.52)	0.49	(0.48, 0.50)	0.75	(0.73, 0.78)
Ovary	1.05	(1.04, 1.06)	1.10	(1.09, 1.11)	0.77	(0.74, 0.80)
Urinary Bladder	0.32	(0.32, 0.33)	0.33	(0.32, 0.33)	0.33	(0.32, 0.35)
Kidney and Renal Pelvis	0.35	(0.34, 0.35)	0.36	(0.35, 0.36)	0.29	(0.28, 0.31)
Brain and Other Nervous System	0.39	(0.38, 0.39)	0.42	(0.41, 0.43)	0.20	(0.19, 0.21)
Thyroid	0.06	(0.06, 0.06)	0.06	(0.06, 0.06)	0.05	(0.05, 0.06)
Hodgkin Lymphoma	0.04	(0.04, 0.04)	0.04	(0.04, 0.04)	0.03	(0.02, 0.03)
Non-Hodgkin Lymphoma	0.77	(0.76, 0.78)	0.81	(0.80, 0.82)	0.44	(0.42, 0.46)
Myeloma	0.39	(0.39, 0.40)	0.37	(0.36, 0.37)	0.66	(0.63, 0.68)
Leukemia	0.71	(0.70, 0.72)	0.74	(0.73, 0.74)	0.56	(0.54, 0.58)
Acute Lymphocytic Leukemia	0.04	(0.03, 0.04)	0.04	(0.04, 0.04)	0.02	(0.02, 0.03)
Chronic Lymphocytic Leukemia	0.15	(0.15, 0.16)	0.16	(0.15, 0.16)	0.12	(0.11, 0.13)
Acute Myeloid Leukemia	0.26	(0.25, 0.26)	0.27	(0.26, 0.27)	0.19	(0.17, 0.20)
Chronic Myeloid Leukemia	0.04	(0.04, 0.04)	0.04	(0.04, 0.04)	0.04	(0.03, 0.05)

Devcan Version 6.2.0, April 2007, National Cancer Institute (<http://srab.cancer.gov/devcan/>).

Source: NCHS public use data file for the total US.

Table I-19 - continued

Lifetime Risk (Percent) of Dying from Cancer by Site and Race/Ethnicity

Females, Total U.S., 2002-2004

Site	Asian/Pacific Islanders	American Indian/ Alaska Natives ^a	Hispanics ^b
	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)
All Sites	16.26 (15.88, 16.65)	16.71 (15.98, 17.50)	15.62 (15.42, 15.82)
Oral Cavity and Pharynx	0.23 (0.18, 0.30)	0.18 (0.12, 0.33)	0.13 (0.11, 0.15)
Esophagus	0.16 (0.12, 0.22)	0.20 (0.11, 0.37)	0.16 (0.14, 0.19)
Stomach	1.13 (1.02, 1.27)	0.63 (0.48, 0.86)	0.78 (0.73, 0.83)
Colon and Rectum	2.06 (1.89, 2.24)	1.80 (1.53, 2.13)	1.77 (1.70, 1.85)
Liver and Intrahepatic Bile Duct	1.17 (1.06, 1.30)	0.89 (0.70, 1.16)	0.77 (0.72, 0.82)
Pancreas	1.27 (1.16, 1.40)	0.83 (0.66, 1.06)	1.19 (1.13, 1.26)
Larynx	0.02 (0.01, 0.06)	0.04 (0.01, 0.17)	0.03 (0.02, 0.04)
Lung and Bronchus	3.10 (2.94, 3.27)	3.75 (3.42, 4.14)	2.25 (2.17, 2.33)
Melanoma of the Skin	0.06 (0.03, 0.12)	0.16 (0.07, 0.35)	0.09 (0.07, 0.11)
Breast	1.74 (1.63, 1.87)	1.94 (1.69, 2.26)	2.08 (2.01, 2.16)
Cervix Uteri	0.32 (0.28, 0.39)	0.38 (0.29, 0.56)	0.35 (0.33, 0.39)
Corpus and Uterus, NOS	0.34 (0.30, 0.41)	0.29 (0.21, 0.45)	0.45 (0.41, 0.48)
Ovary	0.68 (0.62, 0.76)	0.77 (0.60, 1.00)	0.82 (0.77, 0.86)
Urinary Bladder	0.21 (0.17, 0.28)	0.17 (0.09, 0.35)	0.26 (0.23, 0.30)
Kidney and Renal Pelvis	0.18 (0.15, 0.24)	0.52 (0.39, 0.73)	0.35 (0.32, 0.38)
Brain and Other Nervous System	0.20 (0.17, 0.26)	0.14 (0.09, 0.28)	0.29 (0.27, 0.32)
Thyroid	0.11 (0.08, 0.16)	0.09 (0.04, 0.24)	0.08 (0.07, 0.10)
Hodgkin Lymphoma	0.04 (0.02, 0.08)	0.06 (0.02, 0.20)	0.05 (0.04, 0.06)
Non-Hodgkin Lymphoma	0.73 (0.64, 0.83)	0.57 (0.41, 0.81)	0.72 (0.68, 0.77)
Myeloma	0.24 (0.20, 0.30)	0.39 (0.29, 0.57)	0.39 (0.36, 0.43)
Leukemia	0.47 (0.41, 0.56)	0.49 (0.37, 0.69)	0.57 (0.53, 0.61)
Acute Lymphocytic Leukemia	0.03 (0.02, 0.07)	0.04 (0.02, 0.18)	0.06 (0.05, 0.07)
Chronic Lymphocytic Leukemia	0.03 (0.02, 0.07)	0.07 (0.03, 0.22)	0.07 (0.06, 0.09)
Acute Myeloid Leukemia	0.22 (0.17, 0.29)	0.18 (0.12, 0.33)	0.18 (0.16, 0.21)
Chronic Myeloid Leukemia	0.04 (0.02, 0.09)	0.03 (0.01, 0.17)	0.04 (0.03, 0.06)

Devcan Version 6.2.0, April 2007, National Cancer Institute (<http://srab.cancer.gov/devcan/>).

Source: NCHS public use data file for the total US.

^a Underlying mortality data for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.^b Hispanic is not mutually exclusive from whites, blacks, Asian Pacific Islanders, and American Indians/Alaska Natives. Underlying mortality data for Hispanics exclude deaths from Minnesota, New Hampshire and North Dakota.